Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose internationa...
This historical record does not confirm current site availability.
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Belgium · Denmark and 4 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 400
- Sponsor
- Institut de Recherches Internationales Servier [...] 1. Institut de Recherches Internationales Servier 2. Laboratorios Servier S.L. (For Spain only)
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Belgium, Denmark, Hungary, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2005-002388-95
- Official title
Show the full official title
Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose internationa...
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Belgium · Denmark · Hungary
3 more locations
- Italy
- Portugal
- Spain
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Institut de Recherches Internationales Servier [...] 1. Institut de Recherches Internationales Servier 2. Laboratorios Servier S.L. (For Spain only), a research institute.
